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Abstract
Objective To determine whether use of intermediate acting
neuromuscular blocking agents during general anesthesia increases the
incidence of postoperative respiratory complications.
Design Prospective, propensity score matched cohort study.
Setting General teaching hospital in Boston, Massachusetts, United
States, 2006-10.
Participants 18 579 surgical patients who received intermediate acting
neuromuscular blocking agents during surgery were matched by
propensity score to 18 579 reference patients who did not receive such
agents.
Main outcome measures The main outcome measures were oxygen
desaturation after extubation (hemoglobin oxygen saturation <90% with
a decrease in oxygen saturation after extubation of >3%) and
reintubations requiring unplanned admission to an intensive care unit
within seven days of surgery. We also evaluated effects on these
outcome variables of qualitative monitoring of neuromuscular
transmission (train-of-four ratio) and reversal of neuromuscular blockade
with neostigmine to prevent residual postoperative neuromuscular
blockade.
Results The use of intermediate acting neuromuscular blocking agents
was associated with an increased risk of postoperative desaturation less
than 90% after extubation (odds ratio 1.36, 95% confidence interval 1.23
to 1.51) and reintubation requiring unplanned admission to an intensive
care unit (1.40, 1.09 to 1.80). Qualitative monitoring of neuromuscular
transmission did not decrease this risk and neostigmine reversal
increased the risk of postoperative desaturation to values less than 90%
(1.32, 1.20 to 1.46) and reintubation (1.76, 1.38 to 2.26).
Conclusion The use of intermediate acting neuromuscular blocking
agents during anesthesia was associated with an increased risk of
clinically meaningful respiratory complications. Our data suggest that
the strategies used in our trial to prevent residual postoperative
neuromuscular blockade should be revisited.
Introduction
Tensofmillionsofpeopleworldwideundergogeneralanesthesia
every day. Anesthetists use a wide variety of drugs to establish
the reversible state of anesthesia, which is characterised by
hypnosis, amnesia, analgesia, hemodynamic stability with
controlofthestressresponse,andimmobility.
1Deepanesthesia
provides all components
2 3; however, to achieve immobility
with lower levels of anesthetic agents, anesthetists may
coadministercurare-typeneuromuscularblockingagents.These
drugsinhibitneuromusculartransmissionfromnervestomuscles
by competitively blocking the binding of acetylcholine to its
postsynaptic receptors at the motor end plate, thereby causing
paralysis of the muscle.
More than 400 million people receive neuromuscular blocking
agents annually (Intercontinental Marketing Services (IMS)
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Research
RESEARCHHealth, Multinational Integrated Data Analysis System
(MIDAS), September 2010), either in the operating theatre to
optimize surgical conditions, or in the intensive care unit to
facilitatemechanicalventilationinthosewithpatient-ventilator
asynchrony.
4Neuromuscularblockingagentsarealsocommonly
administeredbeforetrachealintubationtoensurehigherquality
oftheprocedureandfewercomplications.Thesedrugsdecrease
intubation associated laryngeal morbidity as well as procedure
related complications when used by experienced intensivists
for emergency intubations.
5-8
Full restoration of a patient’s muscle strength is essential to
ensure a safe postoperative recovery. Lingering effects of
neuromuscular blocking agents, however, may cause partial
paralysis, a condition in which symptoms of muscle weakness
prevailinthepostoperativeperiod.
9Thismayimpairbreathing,
upper airway patency, protective airway reflexes, swallowing,
and coughing, thereby putting patients at risk for serious
complications in the vulnerable postoperative period.
10-15
Unanticipated postoperative intubation is associated with
increasedmortalityandincreasinghealthcarecosts.
16 17Thelong
acting neuromuscular blocking agent pancuronium has been
associated with a higher risk of postoperative respiratory
failure.
18 19 Consequently, long acting compounds have almost
quantitatively disappeared from the market, being replaced by
modern intermediate acting non-depolarizing neuromuscular
blocking agents, but it is unclear if the use of these drugs
represents a risk factor for adverse perioperative respiratory
outcomes.
20
Inadditiontocarefulclinicalassessment,anesthetistscommonly
use two strategies to control the effects of non-depolarizing
neuromuscular blocking agents and restore patients’ optimal
muscle strength. Firstly, the monitoring of neuromuscular
transmission is applied during surgery to assess the degree of
a patient’s neuromuscular block. Most often subjective
(qualitative)visualortactile(palpation)assessmentofamuscle
response to a train-of-four stimulation (series of four electric
stimuli delivered at 2Hz) of a peripheral nerve is measured.
After neuromuscular blocking agents have been administered,
muscles show a decrease (fade) of muscular contraction from
first to fourth response as opposed to muscles with intact or
fullyrestoredneuromusculartransmission,whichshowthesame
responsetoeachstimulus.Secondly,reversalofneuromuscular
blockade with acetylcholinesterase inhibitors is used to
antagonise potentially lingering effects of non-depolarizing
neuromuscular blocking agents at the end of surgery.
Acetylcholinesterase inhibitors like neostigmine increase the
amount of acetylcholine in the synaptic cleft, thereby
counteracting the effects of neuromuscular blocking agents.
21 22
Respiratory failure in the immediate postoperative period is
related to a multiplicity of causes, such as the respiratory
depressant effects of anesthetics, opioids, and neuromuscular
blocking agents, the effects of the surgical trauma, and the
consequences of bleeding and intraoperative hypothermia.
Controlling for these variables to the best of our ability, we
carried out a prospective propensity matched analysis. We
hypothesized that the use of intermediate acting
non-depolarizing neuromuscular blocking agents would be
associatedwithanincreasedriskofpostoperativehypoxicevents
and reintubation requiring unplanned admission to an intensive
careunitandmechanicalventilation.Wealsoexploredwhether
the monitoring of neuromuscular transmission during surgery
and reversal of neuromuscular blockade decrease the risk for
postoperative respiratory adverse events.
Methods
Massachusetts General Hospital is a multidisciplinary, tertiary
care facility and teaching affiliate of Harvard Medical School
in Boston, Massachusetts, United States. More than 40 000
surgical procedures (about 50% each in inpatients and
outpatients) are performed annually. We carried out a
prospective analysis of filed data on all surgical patients who
underwentgeneralanesthesiaatMassachusettsGeneralHospital
from March 2006 to September 2010.
Data sources and study population
Three separate databases were utilized to integrate deidentified
data from the preoperative, intraoperative, and postoperative
period for patients who underwent a surgical procedure in the
mainoperatingsuites.Weincludedsurgicalproceduresinwhich
patients were tracheally intubated and ventilated for surgery
and extubated at the end of surgery. We decided a priori to
include all procedures that met the inclusion criteria rather than
limiting the analysis to individual patients who underwent only
one procedure; respiratory side effects of neuromuscular
blocking agents are mainly procedure and dose specific, and
inclusionofsubsequentproceduresofthesamepatientexplains
additional variance of the interplay between use of
neuromuscular blocking agents and the occurrence of
postoperative respiratory complications. The Anesthesia
Information Management System was installed by the
Department of Anesthesia, Critical Care and Pain Medicine in
2002. It records physiological data streaming from patient
monitors as well as information on medical history and
documentation of important surgery and anesthesia related
events,includingadverseevents,perioperativeprocedures,and
drug and fluid therapy. In addition we used the respiratory
therapyqualityassurancedatabaseandhospitalbillingdatabase.
Retrieved data on the patients’ characteristics and preoperative
medical data included sex, age, body mass index, American
Society of Anesthesiologists physical status classification, and
information on specific illnesses assembled in the Charlson
comorbidity index. The last was calculated using codes of the
International Statistical Classification of Diseases and Related
Health Problems, ninth revision. Details of intraoperative
managementincludedsurgicalspecialty(characterisedasburn,
gynecology, neurosurgery, urology, cardiac, general,
oral/maxillofacial, orthopedic, pediatric, plastic, thoracic,
transplant,traumaandvascular,andsurgicaloncology),duration
of the surgical procedure, emergency status, monitoring of
neuromusculartransmission,andtheuseofvolatileanesthetics,
nitrous oxide, opioids, and the reversal agent neostigmine.
Neuromuscular blocking agents
We screened all anesthetics to determine if neuromuscular
blocking agents were administered during surgery. Agents that
were administered comprised the depolarizing muscle relaxant
succinylcholine,aswellasnon-depolarizingagentsmivacurium
(shortacting),cisatracurium,rocuronium,vecuronium(allthree
intermediate acting), and pancuronium (long acting). In the
statistical analysis we included all anesthetics in which
intermediate acting non-depolarizing neuromuscular blocking
agents were administered to patients intraoperatively. We also
included in the analysis those anesthetics in which patients
additionally or exclusively received succinylcholine for
intubation. Ninety anesthetics were excluded for being
associated with use of pancuronium (83 anesthetics) and
mivacurium (seven anesthetics). Thirty two anesthetics were
excluded because of missing points on core data.
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RESEARCHOutcomes
We chose desaturation after extubation and reintubation as the
primaryoutcomemeasuresandscreenedallthemedicalrecords
for these two respiratory endpoints.
Desaturationafterextubationwasdefinedashemoglobinoxygen
saturationbelow90%andbelow80%duringthefirst20minutes
after extubation with a decrease in oxygen saturation after
extubationofmorethan3%.Ourelectronicrecordofanesthesia
(Metavision) samples data from a pulse oximeter every 20
seconds. For statistical analysis we used the nadir value taken
during 10 epochs of one minute duration each before and after
extubation; we included a desaturation event in the analysis if
these criteria were fulfilled.
Reintubation was defined as any reintubation in the hospital
after primary extubation in the operating room within seven
days of surgery, requiring unplanned admission and ventilation
in the intensive care unit. We excluded reintubations required
for conducting a second surgical procedure.
For patients who underwent surgical procedures and were
identified as being reintubated based on the combination of an
extubation billing code followed by evidence of respiratory
services afterwards, we determined the time between primary
extubationandreintubation,aswellastheproposedmechanism
leading to reintubation. This was achieved by reviewing charts
of all patients who presented with postoperative reintubation
based on billing data.
We evaluated two secondary outcomes, which represent
strategiesusedtopreventresidualpostoperativeneuromuscular
blockade: monitoring of neuromuscular transmission and
reversal of neuromuscular blockade.
Monitoring of neuromuscular transmission was defined as any
subjective, visual, or tactile assessment of the evoked response
of the skeletal muscle to peripheral nerve stimulation.
Measurements are taken during surgery and entered
electronically into the Anesthesia Information Management
System by the anesthetist. The other secondary outcome was
reversal of neuromuscular blockade, which was scored if
neostigmine was administered during surgery and documented
intheAnesthesiaInformationManagementSystem.Additional
secondaryendpoints-includedintheanalysiswerepostoperative
lengthofstayinhospitalandin-hospitalmortality.Weretrieved
both values from the hospital electronic medical record
(discharge summary).
Statistical analysis
Statistical analysis was done using JMP (SAS Institute), SPSS
(version 13.0), and SAS (version 9.2). We considered a two
tailed P value of less than 0.05 as significant. To control for
potential confounding, we used a propensity score matched
cohort design.
Propensity score
Our data came from 46 899 patients, 17% of whom underwent
more than one procedure. The propensity score for a patient is
defined as the probability of being treated, conditional on
pretreatment factors. To identify variables that went into the
decision to treat a patient with a neuromuscular blocking agent,
we polled anesthetists from our department to outline their
decision making process on whether a surgical patient should
or should not receive a neuromuscular blocking agent during
surgery. We then selected covariates from our database to
approximatethisclinicalapproachandalsoincludedriskfactors
chosen a priori for the outcome events. More specifically, we
considered age, sex, body weight, body mass index, American
Society of Anesthesiologists physical status classification,
surgicalspecialty,durationofthesurgicalprocedure,emergency
status, the Charlson comorbidity index,
23 and use of volatile
anesthetics, and nitrous oxide. These variables were then
included in a multivariable logistic regression model, with
intermediate acting non-depolarizing neuromuscular blocking
agents administered intraoperatively as the dependent variable.
We included missing information as indicator in the propensity
score model. We reran the propensity score model and the
matchingprocedureincludinginformationonwhetherapatient
had undergone only one surgical procedure or more than one.
This did not meaningfully change our findings.
Matching
On the basis of our calculated propensity scores, we matched
people who had received at least one non-depolarizing
neuromuscular blocking agent during surgery to those who did
not receive any by using greedy matching.
24 The greedy
matching algorithm first identifies matched pairs (a treated
person and an untreated person) within a closeness range of
0.00001ofthepropensityscore,thenifnomoreindividualscan
be found, the program identifies matched pairs in a range of
0.0001 and so on up to a closeness range of 0.1. We selected
one reference surgical procedure for every patient exposed to
non-depolarizing neuromuscular blocking agents, resulting in
cohorts of 18 579 surgical patients who received at least one
non-depolarizing neuromuscular blocking agent and 18 579
reference surgical patients. We then followed both cohorts for
the occurrence of the outcome events. Using the propensity
score as covariate in a regression outcome model in the entire
study cohort resulted in similar effect estimates, indicating no
strong differential effects among patients who could not be
matched.
25
Outcome models
Finally, we carried out logistic regression analysis to test the
association between intermediate acting non-depolarizing
neuromuscularblockingagentsandthevariousoutcomesinthe
matched cohort. To test the secondary research hypotheses that
monitoring of neuromuscular transmission and reversal of
neuromuscular blockade with neostigmine would influence the
outcome criteria, we applied logistic regression analysis in the
dataset of the propensity score matched cohort. Results are
presented as odds ratios with 95% confidence intervals.
Results
Between 2006 and 2010 a total of 57 068 surgical procedures
were carried out under general anesthesia and intubation in 46
899 patients who met the inclusion criteria (fig 1⇓). After
propensity scores had been calculated, 18 579 patients who
received at least one intermediate acting non-depolarizing
neuromuscular blocking agents were matched to 18 579
reference patients who did not receive such agents.
Total study population
Table 1⇓ shows the characteristics of patients who underwent
surgical procedures in the total study population. Intermediate
acting non-depolarizing neuromuscular blocking agents were
administered to patients undergoing 32 002 procedures in the
following distribution: 66.2% for cisatracurium, 22.9% for
vecuronium, and 11.6% for rocuronium. Only 50% of patients
undergoingsurgicalprocedureswhoreceivedintermediateacting
non-depolarizingneuromuscularblockingagentswerereported
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RESEARCHto have been monitored for neuromuscular transmission, and a
cholinesterase inhibitor (neostigmine) was administered in
63.6% of the patients who underwent surgery. Of the 32 002
surgicalprocedureswherepatientsreceivedintermediateacting
non-depolarizing neuromuscular blocking agents and
neostigmine, 37.2% were also monitored for neuromuscular
transmission.
Propensity matched cohort
Table 2⇓ shows the characteristics of the propensity score
matchedcohorts.Thebaselinecovariateswerebalancedbetween
the treated and untreated groups. Cisatracurium was
administered in 67.1% of surgical procedures, vecuronium in
22.4%, and rocuronium in 11.1%.
Primary outcome: respiratory complications
Of the 18 579 patients who received at least one intermediate
acting non-depolarizing neuromuscular blocking agent, 151
(0.8%) were reintubated, 925 (5.0%) had a desaturation event
with hemoglobin oxygen saturation <90%, 212 (1.1%) had a
desaturation event with hemoglobin oxygen saturation <80%,
and 55 (0.3%) died in hospital. The patients’ hospital length of
stay averaged 4.0 days. Logistic regression analysis showed
that the use of intermediate acting non-depolarizing
neuromuscularblockingagentswasassociatedwithanincreased
risk for both postoperative desaturation (oxygen saturation
<90%, odds ratio 1.36, 95% confidence interval 1.23 to 1.51;
P<0.01, oxygen saturation <80%, 1.66, 1.34 to 2.07; P<0.01)
and postoperative reintubation requiring admission to an
intensive care unit (1.40, 1.09 to 1.80; P <0.01). When
intermediate acting non-depolarizing neuromuscular blocking
agents were administered for surgeries of short duration (<120
minutes), the risk of reintubation was even higher (2.04, 1.44
to 2.90; P<0.01). Table 3⇓ provides a summary of the
associations between the use of intermediate acting
non-depolarizing neuromuscular blocking agents and the
different outcome variables.
Reintubation requiring unplanned admission to an intensive
care unit is a serious complication, which translated to a more
than 90-fold higher risk of dying in hospital (odds ratio 91, 67
to 125; P<0.001). Most of the patients were intubated during
the first three days after surgery, with the peak during the first
24 hours. Data for the entire study period and up to seven days
after extubation was captured and is presented in fig 2⇓, which
shows the day of reintubation in patients where reintubation
could clearly be allocated to a well defined time (fig 2). Fig 3⇓
summarizes the mechanisms leading to respiratory failure and
reintubationasdeterminedbychartreview.Specificinformation
on the mechanisms leading to reintubation could be clearly
identifiedin216outof249patientswhowerereintubatedbased
on information derived from the billing code, 78 of whom were
reintubated in the operating room and 138 out of the operating
room (post-anesthesia care unit, intensive care unit, or on the
surgical floor). Of those, the five most common mechanisms
leading to reintubation (and subsequent unplanned admission
toanintensivecareunit)werepostoperativepulmonaryedema,
pneumonia, atelectasis, impairment of brain function leading
to sedation, and aspiration (fig 3). Clinicians provided multiple
(on average 2.5) reasons why reintubation was required.
Strategies to avoid residual postoperative
neuromuscular blockade
In the propensity score matched cohort, monitoring of
neuromuscular transmission was only applied to half of the
cases(48.9%).Thereversalagentneostigminewasadministered
in 63.2% of the patients, and 36.2% of those who received
neostigmine were also monitored for neuromuscular
transmission.
Use of the reversal agent neostigmine was associated with
desaturation below 90% (odds ratio 1.32, 1.20 to 1.46), as well
as reintubation requiring unplanned admission to an intensive
care unit (1.76, 1.38 to 2.26, table 4⇓). Monitoring of
neuromusculartransmissionwasalsoassociatedwithincreased
riskofthesetwooutcomeevents(table4⇓).However,inpatients
who received neostigmine for reversal, monitoring seemed to
have some beneficial effects. In total, 9401patients who
underwent surgical procedures received both neostigmine for
reversal and monitoring of neuromuscular transmission. In this
subgroupofcases,afterextubationintheoperatingtheatre,low
level hypoxia (oxygen saturation <90%, and oxygen saturation
<93%) occurred less often compared with those who received
neostigminewithoutmonitoringofneuromusculartransmission
(P=0.003 and P<0.001, respectively).
Discussion
Inthislarge,prospectivepropensityscorematchedcohortstudy,
the use of intermediate acting non-depolarizing neuromuscular
blocking agents was associated with adverse postoperative
respiratory outcomes—that is, desaturation after extubation to
a peripheral oxygen saturation of <90% as well as 80%, and
postoperativereintubationrequiringunplannedadmissiontoan
intensive care unit and mechanical ventilation. Qualitative
monitoring of neuromuscular transmission (peripheral
train-of-four nerve stimulation to visually screen for a fade of
contraction) did not significantly modify the risk, and reversal
withneostigmineevenincreasedtheriskofseverepostoperative
respiratory failure.
Comparison to previous studies
Several studies have reported adverse respiratory events after
the use of neuromuscular blocking agents. The early finding
that attracted the most attention and controversy was presented
roughly60yearsagowhenasix-foldhighermortalityratewhen
neuromuscular blocking agents were added to anesthetics was
reported.
26 The authors could not adjust their findings for
important variables affecting mortality, thereby promoting a
potentially misleading relation.
27 In the following 40 years,
further outcome studies have been published to examine the
association between the use of neuromuscular blocking agents
and anesthesia related mortality.
19 26 28 29 One study used a
prospective survey to study all mortality associated with
anesthesia over a period of 10 years.
28 The author reported that
oneofthemaincontributingfactorstoanesthesiarelateddeaths
was respiratory inadequacy after neuromuscular block.
28 Other
authors have reported on data collected by the Association of
Anaesthetists of Great Britain and Ireland based on anonymous
reports of deaths within six days of anesthesia.
29 They found
thatreportedanesthesiarelateddeathscouldmainlybeattributed
to postoperative respiratory failure, which was in many cases
related to management of neuromuscular blocking agents.
29
Researchers of a prospective, multicenter study reported that
thelongactingnon-depolarizingneuromuscularblockingagent
pancuroniumwasassociatedwithahigherriskofpostoperative
pulmonary complications.
19 Despite the introduction of
intermediateactingneuromuscularblockingagents,morerecent
database studies published since the 1990s continue to show
associations between the use of muscle relaxants as well as
partial paralysis potentially related to neuromuscular
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RESEARCHmanagement and adverse postoperative outcomes.
30-32 Our
findings extend those of these reports as we propose that
intermediate acting non-depolarizing neuromuscular blocking
agents are a risk factor for hypoxic events after extubation and
increased reintubation rates. This is important, because
intermediate acting non-depolarizing neuromuscular blocking
agents now represent 80% of the market volume for
neuromuscular blocking agents.
Strategies to prevent postoperative residual
neuromuscular blockade
To help prevent these postoperative adverse effects of muscle
relaxants,cliniciansusetwocommonstrategiestoavoidresidual
neuromuscular blockade and its consequences: intraoperative
monitoringofneuromusculartransmissionandpharmacological
reversalofneuromuscularblockade.Inourstudy,intraoperative
qualitative monitoring of neuromuscular transmission (that is,
visual or tactile identification of a fade of contraction after
train-of-four stimulation of a peripheral nerve) was used by
about 50% of the clinicians but did not help prevent
postoperativerespiratorycomplicationsassociatedwiththeuse
ofneuromuscularblockingagents.Incontrast,otherresearchers
reported that quantitative intraoperative monitoring of
neuromuscular transmission (that is, identification of a
train-of-four fade through acceleromyography monitoring)
11
reducestheriskofresidualneuromuscularblockadeandadverse
respiratory events in the post-anesthesia care unit.
33
Acceleromyography monitoring uses a small piezoelectric
transducer attached to the stimulated muscle to objectively
measuretheforceproducedbyamuscleafternervestimulation.
Whilevisualortactileobservationoffademayenableaclinician
to predominantly identify distinct levels of partial paralysis,
another study supports the view that quantitative monitoring of
neuromuscular transmission may be required to adequately
detect low but clinically meaningful levels of residual
neuromuscular blockade.
34
Pharmacological reversal of muscle relaxants by using
acetylcholinesterase inhibitors in combination with
glycopyrrolate at the end of the surgical procedure has been
associated with a decreased risk of severe postoperative
morbidity and mortality.
31 In contrast, we found no beneficial,
but rather a harmful, association of use of neostigmine on
respiratorycomplications.Reversalofneuromuscularblockade
attheendofsurgeryisimportantforpatients’safetybutitvaries
broadly between countries, medical centers, and anesthetists.
The routine reversal of the effects of neuromuscular blocking
agentsattheendofeverysurgicalprocedureisrarelypromoted
in Europe, whereas antagonizing effects of non-depolarizing
neuromuscularblockingagentsiscommonpracticeintheUnited
States, regardless of whether residual effects of the drugs can
beshown.
35Routinereversalattheendofthesurgicalprocedure
has to be considered carefully and does not always ensure
complete restoration of patients’ muscle strength. On the
contrary, neostigmine may not only cause a variety of side
effects like arrhythmias, dry mouth, and bronchospasm but its
use may have little influence on partial paralysis.
36 In fact it has
been shown to adversely affect neuromuscular function and
causemuscleweaknessinpatientsaswellashealthyvolunteers
when given after complete recovery of neuromuscular
transmission.
35 37-39Morespecifically,whengivenintheabsence
of neuromuscular block, neostigmine can impair upper airway
dilatorvolume,genioglossusmusclefunction,anddiaphragmatic
function,importantfactorstotakeintoaccountwithrespiratory
complications.
21 39Inourstudywehypothesizedthatneostigmine
induced neuromuscular block—that is, the manifestation of a
depolarization block caused by accumulation of acetylcholine
atthemuscleendplate,mayhaveoccurredinthosepatientswho
receivedtheacetylcholinesteraseinhibitoraspartofa“routine”
reversal approach by the end of the surgical procedure without
previous identification of a residual neuromuscular blockade
by monitoring of neuromuscular transmission.
21 38-40 Other
possibledownsidesofneostigminereversalrelatetoitsduration
of action, which may be shorter than the elimination half life
of rocuronium under specific conditions. In practical terms, the
maximum depth of neuromuscular transmission block that can
be sufficiently reversed by neostigmine approximately
corresponds to the reappearance of the fourth muscle response
to train-of-four stimulation.
41 If neostigmine is given during
deep neuromuscular block, absence of fade on subjective
evaluation (such as palpation) of the response to train-of-four
stimulation would mislead most clinicians into believing that
adequate reversal had been achieved. In reference to a previous
study, it is for this reason that antagonism with
acetylcholinesterases is best delayed until at least two to three
and preferably four responses of the stimulated muscle are
achieved by train-of-four stimulation.
35 Considering these
potential drawbacks of neostigmine, its use for reversal is
indicated when a patient’s muscle strength has not recovered
fully at the end of surgery, but the existence of residual
neuromuscular blockade needs to be verified by objective,
quantitative monitoring of neuromuscular transmission before
the reversal agent can safely be administered.
Strengths and weaknesses of the study
The strength of this study is predominantly determined by the
high quality database, which allowed us to focus on clinically
meaningfulendpointswhilecontrollingforavarietyofpotential
confounders. We created a propensity score matched cohort,
which had a balanced risk factor and covariate profile reducing
the possibility of confounding.
Several limitations should be considered when interpreting our
results. The surgical procedure cases included in the registry
are from a specialty medical center, which may limit
generalizability to other settings. While we have no reason to
believe that the effect of neuromuscular blocking agents on our
outcomes was largely different in other centers, differences in
managing perioperative muscle strength across centers may
translate to different effects on respiratory outcome. This study
of medical record data is observational in nature and residual
and immeasurable confounding remains a possibility. In
addition, we used the surgical time and surgical specialty
carryingouttheoperationsasproxiesforthevariousprocedures
(astimeofprocedureandspecialtyarehighlycollinearwiththe
individualprocedures).Intotal,morethan5000singlecategories
were recorded, indicating various procedures. Adding this
information to a multivariable model would not result in
meaningful estimates. Finally, despite best efforts to gather
complete and accurate data for each patient, it is not possible
to rule out potential misclassification. This should, however,
be non-differential.
Possible biological explanations
Agrowingbodyofevidencefromvolunteerstudiesandoutcome
studies suggests that adverse respiratory effects of
non-depolarizing neuromuscular blocking agents are probably
due to their lingering effects after surgery.
10-15 Residual
neuromuscular blockade increases the vulnerability of the
respiratory system in such a way that adverse subclinical signs
andsymptomsoccur.
12 15Residualneuromuscularblockadealso
increases the incidence of adverse respiratory events in the
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RESEARCHpost-anesthesia care unit, such as jaw thrust requirement, and
increases the length of stay in the unit,
10 13-15 even after use of
intermediate acting non-depolarizing neuromuscular blocking
agents.
42 Researchers found that residual paralysis was present
in 45% of the cases on arrival in the post-anesthesia care unit
up to two hours after use of a single dose of an intermediate
acting muscle relaxant.
42 On the basis of our data we speculate
thatlingeringeffectsofneuromuscularblockingagentsincrease
the risk of respiratory vulnerable patients to develop a
respiratory compromise,
10 12-15 leading to unplanned admission
to an intensive care unit. In accordance, in our study the risk of
severe respiratory complications was higher in patients
undergoingshort(<2hours)surgicalprocedures,wherethetime
between use of neuromuscular blocking agents to facilitate
intubationandextubationmaynothavebeenlongenough.Most
ofthepatientsundergoingsurgicalproceduresinourstudywere
reintubated for pulmonary edema, pneumonia, atelectasis, and
aspiration. Based on this information, we conclude that it is
possible that residual paralysis on the first day after surgery
may be a contributing factor to reintubation on a subsequent
day. Partial paralysis affects the ability to protect the airway
during swallowing and should thereby increase the propensity
to aspirate or develop pneumonia. The proposed mechanism of
pulmonaryedemamaybenegativepressurepulmonaryedema;
paralyticscaninduceanupperairwayobstructionintheabsence
of respiratory pump muscle dysfunction.
43
Meaning of the study: implications for
clinicians
IntheUnitedStates,about20millionpatientseachyearreceive
general anesthesia for surgery,
44 and more than 100 000 000
units of muscle relaxants are being used in the United States in
the operating theatre, emergency departments, and on the
intensive care units. This study shows that the use of modern
intermediate acting non-depolarizing neuromuscular blocking
agents may put patients at risk for postoperative respiratory
complications. Reintubation after surgery increases mortality
and healthcare costs,
16 17 thus highlighting the potential
implications of our results in terms of both patient safety and
healthcare economics. Assuming causality, our results indicate
that 26% of desaturation less than 90%, 40% of desaturation
less than 80%, and 29% of reintubations would be attributable
tointermediateactingnon-depolarizingneuromuscularblocking
agents.
Themortalityofpostsurgicalpatientswithunplannedadmission
to an intensive care unit is high, with respiratory complications
being the most important problem.
45 In our data, patients who
needed reintubation requiring unplanned admission to an
intensive care unit had a more than 90-fold higher risk of dying
in the hospital (odds ratio 91, 95% confidence interval 67 to
125) than patients who did not require intubation. In addition,
critical care medicine is expensive. In the United States,
treatment of critically ill patients represents nearly 1% of the
gross domestic product and 25% of a typical hospital budget.
Therefore, all efforts should be undertaken to reduce factors
that contribute to unplanned admissions to an intensive care
unit.
Desaturation after extubation may be influenced by many
factors, such as the lingering effects of anesthetics, opioids, or
neuromuscularblockingagents;thesurgicaltrauma;orincreased
oxygen consumption from pain or sepsis. In addition, oxygen
levels before extubation and the technique for extubation are
likely important contributors. Our data show that the
intraoperative use of intermediate acting non-depolarizing
neuromuscular blocking agents, independent of common risk
factors of respiratory outcome, is associated with severe
postoperative pulmonary complications. Therefore, efforts
should be made to optimize the use of neuromuscular blocking
agents that have been shown to improve outcomes under well
defined conditions.
8
Unanswered questions and future research
Our data raise concern about the potential adverse outcome
eventsofnon-depolarizingneuromuscularblockingagents,and
further targeted research is warranted to resolve remaining
questions.Forexample,itisuncleariftherespiratorymorbidity
associatedwithneuromuscularblockingagentscanbemitigated
by optimal clinical management such as the use of reversal
agents and qualitative or quantitative monitoring of
neuromuscular transmission or use of newer reversal agents
such as sugammadex.
33 46 In summary, we found that use of
intermediate acting neuromuscular blocking agents during
anesthesia leads to an increased risk of developing clinically
meaningful respiratory complications.
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RESEARCHTables
Table 1| Characteristics of study population according to whether or not intermediate acting non-depolarizing neuromuscular blocking
agents were administered intraoperatively. Values are frequencies (percentages) unless stated otherwise
Neuromuscular blocking agents
Subgroups Not administered (n=25 066) Administered (n=32 002)
Age (years):
1495 (6.0) 966 (3.0) <10
1415 (5.7) 1383 (4.3) 10-19
1874 (7.5) 2362 (7.4) 20-29
2547 (10.2) 3276 (10.3) 30-39
4424 (17.7) 5102 (16.0) 40-49
4872 (19.4) 6154 (19.2) 50-59
4258 (17.0) 5813 (18.2) 60-69
2360 (9.4) 3801 (11.9) 70-79
936 (3.7) 1821 (5.7) ≥80
885 (3.5) 1324 (4.1) Missing
47.6 (20.7) 51.2 (19.8) Mean (SD)
13 054 (52.1) 17 294 (54.0) Female
12 012 (47.9) 14 708 (46.0) Male
Body weight fifths (kg):
4710 (18.8) 5504 (17.2) <60
4332 (17.3) 5664 (17.7) 60-69.9
4510 (18.0) 6026 (18.8) 70-80.9
4419 (17.6) 5783 (18.1) 81-94.9
4315 (19.9) 5974 (18.7) ≥95
2780 (11.1) 3051 (9.5) Missing
75.9 (26.6) 77.8 (24.6) Mean (SD)
ASA status:
5201 (20.8) 4581 (14.3) 1
14 568 (58.1) 18 330 (57.3) 2
4645 (18.5) 8165 (25.5) 3
222 (0.9) 446 (1.4) ≥4
430 (1.7) 480 (1.5) Missing
2.0 (0.7) 2.1 (0.7) Mean (SD)
Charlson comorbidity index:
15 152 (60.5) 15 597 (48.7) 0
3329 (13.3) 5742 (17.9) 1
1848 (7.4 2948 (9.2) 2
2662 (10.2) 3940 (12.3) 3
1062 (4.2) 1934 (6.0) 4
360 (1.4) 689 (2.2) 5
653 (2.6) 1152 (3.6) ≥6
1.4 (2.3) 1.1 (2.1) Mean (SD)
Surgical specialty:
248 (1.0) 373 (1.2) Burn
18 (0.1) 86 (0.3) Cardiac surgery
2758 (11.0) 5337 (16.7) General surgery
2128 (8.5) 2642 (8.3) Gynecology
1219 (4.9) 3062 (9.6) Neurosurgery
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RESEARCHTable 1 (continued)
Neuromuscular blocking agents
Subgroups Not administered (n=25 066) Administered (n=32 002)
349 (1.4) 959 (3.0) Oral/maxillofacial surgery
6355 (25.4) 6094 (19.0) Orthopedic surgery
1684 (6.7) 1250 (3.9) Pediatric surgery
953 (3.8) 1599 (5.0) Plastic surgery
2590 (10.3) 1336 (4.2) Surgical oncology
1418 (5.7) 3118 (9.7) Thoracic surgery
384 (1.5) 548 (1.7) Transplant surgery
630 (2.5) 1837 (5.7) Trauma surgery
3377 (13.5) 1998 (6.2) Urology
479 (1.9) 1376 (4.3) Vascular surgery
226 (0.9) 45 (0.1) Other
250 (1.0) 342 (1.1) Missing
Duration of surgery (min):
18 774 (76.3) 20 432 (64.1) <120
5846 (23.7) 11 445 (35.9) ≥120
446 (1.8) 125 (0.4) Missing
86.8 (94.4) 111.3 (92.8) Mean (SD)
734 (2.9) 1698 (5.3) Emergency case
430 (1.7) 480 (1.5) Missing
Volatile anesthetics:
22 841 (91.1) 29 764 (93.0) Any
1437 (5.7) 1639 (5.1) Desflurane
3451 (13.8) 10 003 (31.3) Isoflurane
19 066 (76.1) 20 459 (63.9) Sevoflurane
21 401 (85.4) 26 801 (83.8) Nitrous oxide
Strategies to avoid residual neuromuscular blockade:
NA 20 351 (63.6) Neostigmine
NA 15 997 (50.0) Neuromuscular transmission monitoring
NA 11 905 (37.2) Neostigmine plus neuromuscular transmission monitoring
ASA=American Society of Anesthesiologists; NA=not applicable. Percentages may not add up to 100% because of rounding.
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RESEARCHTable 2| Characteristics of cases in propensity score matched cohort (n=37 158) of patients who did or did not receive at least one
intermediate acting non-depolarizing neuromuscular blocking agent. Values are frequencies (percentages) unless stated otherwise
Neuromuscular blocking agents
Subgroups Not received (n=18 579) Received (n=18 579)
Age (years):
733 (4.0) 795 (4.3) 1-9
938 (5.1) 958 (5.2) 10-19
1419 (7.6) 1446 (7.8) 20-29
1971 (10.6) 1951 (10.5) 30-39
3220 (17.3) 3193 (17.2) 40-49
3738 (20.1) 3707 (20.0) 50-59
3268 (17.6) 3252 (17.5) 60-69
1831 (9.9) 1840 (9.9) 70-79
759 (4.1) 750 (4.0) ≥80
702 (3.8) 687 (3.7) Missing
49.1 (19.8) 48.9 (20.0) Mean (SD)
9535 (51.3) 9638 (51.9) Female
9044 (48.7) 8941 (48.1) Male
Body weight (kg):
3150 (17.0) 3265 (17.6) <60
3217 (17.3) 3225 (17.4) 60-69.9
3441 (18.5) 3416 (18.4) 70-80.9
3386 (18.2) 3259 (17.5) 81-94.9
3526 (19.0) 3579 (19.3) ≥95
1859 (10.0) 1835 (9.9) Missing
77.1 (25.8) 77.5 (25.8) Mean (SD)
ASA score:
3182 (17.1) 3230 (17.4) 1
10 905 (58.7) 10 892 (58.6) 2
3989 (21.5) 3965 (21.3) 3
196 (1.1) 202 (1.1) ≥4
307 (1.7) 290 (1.6) Missing
2.1 (0.7) 2.1 (0.7) Mean (SD)
Charlson comorbidity index:
10 083 (54.3) 10 069 (54.2) 0
2891 (15.6) 2945 (15.9) 1
1555 (8.4) 1566 (8.4) 2
2248 (12.1) 2212 (11.9) 3
922 (5.0) 940 (5.1) 4
329 (1.8) 312 (1.7) 5
551 (3.0) 535 (2.9) ≥6
1.3 (2.2) 1.3 (2.2) Mean (SD)
Surgical specialty:
235 (1.3) 217 (1.2) Burn
18 (0.1) 26 (0.1) Cardiac surgery
2624 (14.1) 2783 (15.0) General surgery
1581 (8.5) 1486 (8.0) Gynecology
1200 (6.5) 1267 (6.8) Neurosurgery
347 (1.9) 356 (1.9) Oral/maxillofacial surgery
4546 (24.5) 4397 (23.7) Orthopedic surgery
921 (5.0) 974 (5.2) Pediatric surgery
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RESEARCHTable 2 (continued)
Neuromuscular blocking agents
Subgroups Not received (n=18 579) Received (n=18 579)
876 (4.7) 823 (4.4) Plastic surgery
1198 (6.5) 1317 (7.1) Surgical oncology
1391 (7.5) 1320 (7.1) Thoracic surgery
353 (1.9) 328 (1.8) Transplant surgery
624 (3.4) 641 (3.5) Trauma surgery
1967 (10.6) 1924 (10.4) Urology
470 (2.5) 479 (2.6) Vascular surgery
26 (0.1) 45 (0.2) Other
202 (1.1) 196 (1.1) Missing
Duration of surgery (min):
12 836 (69.1) 12 609 (67.9) <120
5652 (30.4) 5845 (31.5) ≥120
91 (0.5) 125 (0.7) Missing
102.6 (101.5) 100.1 (95.4) Mean (SD)
672 (3.6) 635 (3.4) Emergency case
307 (1.7) 290 (1.6) Missing
17 103 (92.1) 17 134 (92.2) Volatile anesthetics
15 729 (84.7) 15 803 (85.1) Nitrous oxide
Strategies to avoid residual neuromuscular blockade:
NA 11 737 (63.2) Neostigmine
NA 9081 (48.9) Neuromuscular transmission monitoring
NA 6732 (36.2) Neostigmine plus neuromuscular transmission monitoring
ASA=American Society of Anesthesiologists; NA=not applicable. Percentages may not add up to 100% because of rounding.
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RESEARCHTable 3| Association between use of intermediate acting non-depolarizing neuromuscular blocking agents and outcomes in propensity
score matched cohort (n=37 158)
Odds ratio (95% CI)
Neuromuscular blocking agents
Outcomes Received (n=18 579) Not received (n=18 579)
1.36 (1.23 to 1.51) 925 689 Desaturation <90%
1.66 (1.34 to 2.07) 212 128 Desaturation <80%
1.40 (1.09 to 1.80) 151 108 Reintubation
1.15 (0.78 to 1.69) 55 48 In-hospital death
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RESEARCHTable 4| Association between strategies to prevent partial neuromuscular blockade after surgery (neostigmine reversal and neuromuscular
transmission monitoring) and outcomes in propensity score matched cohort (n=37 158)
Odds ratio (95% CI) Neuromuscular transmission monitoring
Odds ratio (95% CI)
Neostigmine
Outcomes
Applied (n=12 877) Not applied (n=24 281) Administered(n=16
041)
Not administered
(n=21 117)
1.19 (1.07 to 1.32) 621 993 1.32 (1.20 to 1.46) 804 810 Desaturation <90%
1.15 (0.93 to 1.44) 129 211 1.17 (0.95 to 1.45) 160 180 Desaturation <80%
1.49 (1.16 to 1.90) 114 145 1.76 (1.38 to 2.26) 148 111 Reintubation
1.06 (0.71 to 1.58) 37 66 1.02 (0.69 to 1.51) 45 58 In-hospital death
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RESEARCHFigures
Fig 1 Study design
Fig 2 Time of extubation to reintubation based on chart review
Fig 3 Reasons for reintubation in patients undergoing surgical procedures and reintubated after surgery in post-anesthesia
care unit, on the surgical floor, or on the intensive care unit. Data taken from chart review. Data given from patients only
with clear documentation of cause and effect relation between mechanism of respiratory disease and intubation (n=177).
Multiple reasons (on average 2.5 per reintubation) were provided
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